logo
Newly released CDC data shows U.S. fertility rate reached a new low in 2024

Newly released CDC data shows U.S. fertility rate reached a new low in 2024

Fast Company2 days ago
The fertility rate in the U.S. dropped to an all-time low in 2024 with less than 1.6 kids per woman, new federal data released Thursday shows.
The U.S. was once among only a few developed countries with a rate that ensured each generation had enough children to replace itself — about 2.1 kids per woman. But it has been sliding in America for close to two decades as more women are waiting longer to have children or never taking that step at all.
The new statistic is on par with fertility rates in western European countries, according to World Bank data.
Alarmed by recent drops, the Trump administration has taken steps to increase falling birth rates, like issuing an executive order meant to expand access to and reduce costs of in vitro fertilization and backing the idea of 'baby bonuses' that might encourage more couples to have kids.
But there's no reason to be alarmed, according to Leslie Root, a University of Colorado Boulder researcher focused on fertility and population policy.
'We're seeing this as part of an ongoing process of fertility delay. We know that the U.S. population is still growing, and we still have a natural increase — more births than deaths,' she said.
The U.S. Centers for Disease Control and Prevention released the statistic for the total fertility rate with updated birth data for 2024.
In the early 1960s, the U.S. total fertility rate was around 3.5, but plummeted to 1.7 by 1976 after the Baby Boom ended. It gradually rose to 2.1 in 2007 before falling again, aside from a 2014 uptick. The rate in 2023 was 1.621, and inched down in 2024 to 1.599, according to the CDC's National Center for Health Statistics.
Birth rates are generally declining for women in most age groups — and that doesn't seem likely to change in the near future, said Karen Guzzo, director of the Carolina Population Center at the University of North Carolina.
People are marrying later and also worried about their ability to have the money, health insurance and other resources needed to raise children in a stable environment.
'Worry is not a good moment to have kids,' and that's why birth rates in most age groups are not improving, she said.
Asked about birth-promoting measures outlined by the Trump administration, Guzzo said they don't tackle larger needs like parental leave and affordable child care.
'The things that they are doing are really symbolic and not likely to budge things for real Americans,' she said.
Increase in births in new data
The CDC's new report, which is based on a more complete review of birth certificates than provisional data released earlier this year, also showed a 1% increase in births — about 33,000 more — last year compared to the prior year.
That brought the yearly national total to just over 3.6 million babies born.
But this is different: The provisional data indicated birth rate increases last year for women in their late 20s and 30s. However, the new report found birth rate declines for women in their 20s and early 30s, and no change for women in their late 30s.
What happened? CDC officials said it was due to recalculations stemming from a change in the U.S. Census population estimates used to compute the birth rate.
That's plausible, Root said. As the total population of women of childbearing age grew due to immigration, it offset small increases in births to women in those age groups, she said.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Wells Fargo Cuts Elevance (ELV) Price Target on Margin Uncertainty
Wells Fargo Cuts Elevance (ELV) Price Target on Margin Uncertainty

Yahoo

timean hour ago

  • Yahoo

Wells Fargo Cuts Elevance (ELV) Price Target on Margin Uncertainty

Elevance Health, Inc. (NYSE:ELV) ranks among the . Wells Fargo kept its Overweight rating on Elevance Health, Inc. (NYSE:ELV) on July 15, but lowered its price target on the health insurer from $478 to $400. Wells Fargo applied a lower multiple of 10.5x to its 2026 earnings per share projection of $38.05, which is less than the previous multiple of 11.5x. designer491/ Wells Fargo stated that the primary driver of the reduced value multiple was uncertainty regarding margins in the Medicaid, Medicare Advantage (MA), and Health Insurance Exchange (HIX) segments for 2025. The firm also pointed out that there was 'relatively low visibility to improvement in 2026,' especially in the Medicaid and Health Insurance Exchange segments. However, it insisted that Elevance's valuation 'remains compelling once dust settles on estimates.' Elevance Health, Inc. (NYSE:ELV), previously Anthem, Inc., is a leading health-benefits provider in the United States. The company offers medical, pharmaceutical, dental, long-term care, disability, and behavioral health insurance under numerous brands, including Anthem Blue Cross, Blue Shield, Wellpoint, and Carelon. While we acknowledge the potential of ELV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Hulk Hogan Underwent 25 Surgeries Before His Heartbreaking Death
Hulk Hogan Underwent 25 Surgeries Before His Heartbreaking Death

Yahoo

timean hour ago

  • Yahoo

Hulk Hogan Underwent 25 Surgeries Before His Heartbreaking Death

Hulk Hogan Underwent 25 Surgeries Before His Heartbreaking Death originally appeared on Parade. Wrestling icon Hulk Hogan has died at the age of 71, following a reported cardiac arrest. The shocking news comes after Hogan opened up about his declining health and the toll his legendary wrestling career had taken on his body. Hulk Hogan Had 25 Surgeries in 10 Years In a September 2024 appearance on Logan Paul's 'IMPAULSIVE' podcast, Hogan revealed that he had undergone a staggering 25 surgeries over the past decade. 'I've had like 25 surgeries in the last ten years. Ten of them were back surgeries,' Hogan told Paul. 'Nobody told me this gimmick stuff was fake. I've had 10 back surgeries, both knees and both hips replaced, shoulders — everything.' The WWE Hall of Famer also reflected on the physically punishing early days of professional wrestling. He recalled how Andre the Giant once warned him about the dangerous condition of older wrestling rings. 'The equipment back in the day when I started wrestling in '77 was a little different than the rings and stuff you guys are working in now,' Hogan said. 'Andre used to tell me, 'Boss, don't fall down. You won't get back up.' It was like a 22-foot boxing ring that had lumps in it, boards sticking up—it was horrible.' Hulk Hogan's Health Issues Before His Death In the months leading up to his death, Hogan's public appearances sparked concern among fans. After appearing on Fox & Friends to promote his new wrestling league, many noted the WWE icon looked 'unwell.' Soon after, Hogan was reportedly hospitalized for neck and back issues, undergoing a minor cervical fusion surgery. Rumors quickly spread that he was on his 'deathbed,' but his representatives shut down those claims. 'He just needs from time to time a medical check-up,' a spokesperson reportedly told The Independent, adding there were 'no reasons to panic.' Hulk Hogan's Cause of Death: Cardiac Arrest Reported As of now, Hogan's cause of death is being reported as cardiac arrest, though official confirmation and more details are expected in the coming days. Hulk Hogan Underwent 25 Surgeries Before His Heartbreaking Death first appeared on Parade on Jul 24, 2025 This story was originally reported by Parade on Jul 24, 2025, where it first appeared.

Cogent Biosciences Rated as a Buy at Citi on Robust Pipeline
Cogent Biosciences Rated as a Buy at Citi on Robust Pipeline

Yahoo

timean hour ago

  • Yahoo

Cogent Biosciences Rated as a Buy at Citi on Robust Pipeline

Cogent Biosciences, Inc. (NASDAQ:COGT) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 18, Citi raised its price target of the stock to $22 from $15 while maintaining a 'Buy' rating. A doctor reading the results of a Phase 2 clinical trial of treatments for cancer, infectious diseases and autoimmune and inflammatory diseases. The price target hike comes as the company delivers top-line results from bezuclastinib (bezu) in non-advanced systemic mastocytosis (NonAdvSM). According to Citi, investors are increasingly viewing bezuclastinib as an improvement over Blueprint's Ayvakit. The research firm expects the company to deliver positive symptom and biomarker data at ASH in December. Beyond bezuclastinib, Cogent Biosciences is also advancing its other pipeline candidates. The company plans to release advanced systemic mastocytosis (AdvSM) data from the APEX trial in the second half of the year. It will also provide results from the PEAK trial for gastrointestinal stromal tumors (GIST). Cogent Biosciences, Inc. (NASDAQ:COGT) is a biotechnology company that develops precision therapies for genetically defined diseases. It focuses on diseases caused by genetic mutations. Its lead program, bezuclastinib, is a tyrosine kinase inhibitor designed to target the KIT D816V mutation, which drives systemic mastocytosis, as well as other mutations in KIT exon 17. While we acknowledge the potential of COGT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Goldman Sachs REIT Stocks: Top 12 Stock Picks. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store